TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06941025: Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Br

Sponsor: Chiesi Farmaceutici S.p.A. · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 20 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$1,390,500

Rescue Site Savings

+$927,000

Unlock Full NCT06941025 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06941025 Rescue Dossier →